Furosemide

Generic Name: Furosemide

Brand Names: Furoscix, Lasix

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₁ClN_₂O_₅S

CAS Number: 54-31-9

Unique Ingredient Identifier: 7LXU5N7ZO5

Background: Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrol...

Indication: Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.
...

Associated Conditions: Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion

Associated Therapies: -

Clinical Trials

Furosemide Stress Test as a Predictor of Tubular Function in Chronic Kidney Disease

Phase 3

Conditions: Chronic Kidney Disease

Interventions: Drug: Furosemide

First Posted Date: 2015-04-16

Last Posted Date: 2015-04-16

Lead Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez

Target Recruit Count: 100

Registration Number: NCT02417883

Locations: 🇲🇽
Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, DF, Mexico

Early Diuresis Following Colorectal Surgery

Phase 4

Completed

Conditions: Colorectal Disorders

Interventions: Drug: Furosemide
Drug: Celecoxib
Drug: Gabapentin

First Posted Date: 2015-01-30

Last Posted Date: 2018-05-07

Lead Sponsor: Mayo Clinic

Target Recruit Count: 123

Registration Number: NCT02351934

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Impact of Rational Control of Fluid Balance in the Intensive Care Unit

Phase 3

Completed

Conditions: Fluid Overload
Fluid Balance of ICU Patients

Interventions: Drug: Furosemide

First Posted Date: 2015-01-26

Last Posted Date: 2021-08-10

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 171

Registration Number: NCT02345681

Locations: 🇫🇷
CHD Vendée, La Roche sur Yon, France
🇫🇷
Hôpital François Mitterand, Dijon, France
🇫🇷
CHU de Nantes, Nantes, France

A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.

Phase 2

Completed

Conditions: Cutaneous Warts

Interventions: Drug: Vehicle topical
Drug: Digoxin
Drug: CLS003
Drug: Furosemide

First Posted Date: 2015-01-07

Last Posted Date: 2016-07-28

Lead Sponsor: Maruho Co., Ltd.

Target Recruit Count: 81

Registration Number: NCT02333643

Locations: 🇳🇱
LUMC/Centre for Human Drug Research, Leiden, Netherlands

Delayed Renal Allograft Function and Furosemide Treatment

Phase 2

Withdrawn

Conditions: Delayed Graft Function

Interventions: Drug: Placebo
Drug: Furosemide

First Posted Date: 2014-12-09

Last Posted Date: 2016-11-25

Lead Sponsor: Loma Linda University

Registration Number: NCT02312115

Locations: 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States

Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin
Drug: Digoxin
Drug: Furosemide
Drug: Metformin hydrochloride
Drug: Rosuvastatin

First Posted Date: 2014-09-04

Last Posted Date: 2023-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02231931

Locations: 🇩🇪
352.2082.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Aquaresis Utility for Hyponatremic Acute Heart Failure Study

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: Tolvaptan
Drug: Furosemide

First Posted Date: 2014-07-08

Last Posted Date: 2019-05-28

Lead Sponsor: University of Southern California

Target Recruit Count: 33

Registration Number: NCT02183792

Locations: 🇺🇸
Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸
LAC+USC Medical Center, Los Angeles, California, United States

Diuretics for Postpartum High Blood Pressure in Preeclampsia

Phase 4

Completed

Conditions: Preeclampsia

Interventions: Drug: Placebo
Drug: FUROSEMIDE

First Posted Date: 2014-06-13

Last Posted Date: 2024-10-02

Lead Sponsor: Instituto Materno Infantil Prof. Fernando Figueira

Target Recruit Count: 120

Registration Number: NCT02163655

Locations: 🇧🇷
IMIP, Recife, Pernambuco, Brazil

Effectiveness of a Diuretic Algorithm in Clinical Stability in Heart Failure Patients

Not Applicable

Completed

Conditions: Heart Failure

Interventions: Drug: Furosemide and Phone contact
Drug: Furosemide

First Posted Date: 2014-02-21

Last Posted Date: 2020-04-22

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 206

Registration Number: NCT02068937

Locations: 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)

Not Applicable

Withdrawn

Conditions: Congestive Heart Failure

Interventions: Drug: furosemid/spironolactone
Drug: metolazone/spironolactone
Drug: metolazone
Drug: Furosemide

First Posted Date: 2014-01-28

Last Posted Date: 2016-09-07

Lead Sponsor: Yonsei University

Registration Number: NCT02047422

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy